Clinical trials
Observational Multiple Sclerosis trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 4 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 7 |
| Bayer | 4 |
| University Hospital Ostrava | 3 |
| Charles University, Czech Republic | 2 |
| Novartis Pharmaceuticals | 2 |
| Brno University Hospital | 1 |
| Faculty Hospital Kralovske Vinohrady | 1 |
| IMPULS Endowment Fund | 1 |
| IRCCS San Raffaele | 1 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 25 |
| Multiple Sclerosis, Relapsing-Remitting | 3 |
| Disease Progression | 2 |
| Lower Urinary Tract Symptoms | 2 |
| Alopecia Areata | 1 |
| Anemia, Pernicious | 1 |
| Arthritis, Rheumatoid | 1 |
| Autoimmune Diseases | 1 |
| COVID-19 | 1 |
| Colitis, Ulcerative | 1 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.